Michael Dant, MD
Family Medicine · Ringgold, GANPI 1518944081
Payments from drug & device makers
Across 274 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$834
- Pfizer$534
- Astellas Pharma US Inc$415
- Novo Nordisk$356
- Abbott$305
- GSK$283
- plus $2K from 29 others
What the payments were for
- Food & beverage$4,437100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 54 | $834 |
| Pfizer | 39 | $534 |
| Astellas Pharma US Inc | 24 | $415 |
| Novo Nordisk | 22 | $356 |
| Abbott | 17 | $305 |
| GSK | 16 | $283 |
| E.r. Squibb & Sons, L.L.C. | 11 | $180 |
| Dexcom, Inc. | 6 | $177 |
| Novartis | 10 | $175 |
| Amgen | 12 | $170 |
| Biohaven Pharmaceuticals, Inc. | 12 | $158 |
| Supernus Pharmaceuticals, Inc. | 8 | $107 |
| Johnson & Johnson | 6 | $98 |
| AstraZeneca | 6 | $84 |
| Heartflow, Inc. | 1 | $78 |
| Lilly USA, LLC | 4 | $70 |
| Sanofi-aventis U.S. LLC | 4 | $61 |
| Medtronic | 2 | $35 |
| Bayer | 2 | $35 |
| Boston Scientific | 2 | $32 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 2 | $21 |
| Upsher-smith Laboratories LLC | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Mylan Specialty L.p. | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Merck | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Irhythm Technologies, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $14 |
| Smith+Nephew | 1 | $13 |
How this compares
$4,450 in reported general payments places this provider in the 80th percentile of 3,111 family medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 185 | $168,975 |
| JanuviaSitagliptin Phosphate | 73 | $86,862 |
| OzempicSemaglutide | 73 | $82,453 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 62 | $43,667 |
| JardianceEmpagliflozin | 41 | $42,237 |
| FarxigaDapagliflozin Propanediol | 45 | $35,978 |
| LinzessLinaclotide | 36 | $33,487 |
| XareltoRivaroxaban | 38 | $30,360 |
| EntrestoSacubitril/Valsartan | 34 | $30,208 |
| RybelsusSemaglutide | 19 | $29,867 |
| TrulicityDulaglutide | 13 | $28,411 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 13 | $20,462 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $20,020 |
| Tresiba Flextouch U-100Insulin Degludec | 25 | $15,673 |
| VascepaIcosapent Ethyl | 24 | $14,768 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $534 | $182,411229 claims |
| Novo NordiskOzempic, Rybelsus | $356 | $112,32092 claims |
| MerckJanuvia | $17 | $86,86273 claims |
| GSKTrelegy Ellipta, Shingrix, Arnuity Ellipta | $283 | $59,533131 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $19 | $52,93861 claims |
| AbbVieLinzess, Savella, Synthroid | $834 | $42,842107 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $70 | $41,33026 claims |
| AstraZenecaFarxiga | $84 | $35,97845 claims |
| Johnson & JohnsonXarelto | $98 | $30,36038 claims |
| NovartisEntresto | $175 | $30,20834 claims |
| Sanofi-aventis U.S. LLCLantus | $61 | $3,28628 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Ringgold
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
- Nadia CameronAtlanta$2.1M
- John LentzSnellville$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.